CD8A and neoplasm: demonstrated that mice achieving a major response to neoadjuvant PD-1 inhibitors plus chemotherapy exhibited significant infiltration of anti-tumor immune cells, including CD8+ CD44+ CD62L- effector T cells and CD8+ T cells, along with a high M1/M2 macrophage ratio (40).